The success of GLP-1 receptor agonists and SGLT2 inhibitors, which we have discussed from a mechanistic angle, translates to clinical practice as well—these agents are now proven to reduce cardiovascular and renal events in T2D beyond glycemic control [276,277]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.